Form 4: PLRX COO Minnie Kuo Granted 300,000 Stock Options

Pliant Therapeutics' Chief Operating Officer, Minnie Kuo, was granted 300,000 stock options with an exercise price of $1.30, vesting monthly over four years.

Summary

• Minnie Kuo, Chief Operating Officer of Pliant Therapeutics, Inc. (PLRX), was granted 300,000 stock options.
• The options have an exercise price of $1.30 per share.
• The transaction date for the grant was January 22, 2026.
• The options will vest in substantially equal monthly installments, specifically 1/48th of the total, on each monthly anniversary of January 1, 2026, contingent on continuous service to the Issuer.
• The options are set to expire on January 22, 2036.
• Following this transaction, Minnie Kuo beneficially owns 300,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management's long-term commitment and alignment with shareholder interests. It's a standard compensation practice, so not exceptionally positive, but certainly not negative.

Positives

• The grant of 300,000 stock options to a key executive, Minnie Kuo, aligns her interests with the long-term shareholder value of Pliant Therapeutics.
• The 48-month vesting schedule encourages long-term retention and sustained performance from the Chief Operating Officer.

Risks

• The ultimate value of the stock options is contingent on the future performance of PLRX common stock; if the stock price does not exceed the $1.30 exercise price, the options may not be in-the-money.
• The options are subject to a vesting schedule, requiring the reporting person to maintain continuous service to the issuer to fully realize the benefit.

Future Outlook

The grant of stock options to a key executive suggests a long-term commitment to the company's future growth and performance, aligning executive incentives with shareholder interests over the vesting period.

Industry Context

Executive stock option grants are a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key talent. This aligns executive interests with long-term drug development and commercialization success, which is particularly relevant for companies like Pliant Therapeutics that are often in development stages.

Comparison to Industry Standards

• The grant of stock options to a Chief Operating Officer is a common compensation practice in the biotech sector, comparable to similar grants at companies like Moderna, BioNTech, or Regeneron, which utilize equity incentives to motivate leadership.
• A 4-year vesting schedule (implied by 1/48th monthly) is standard for executive equity awards across many industries, including biotech, ensuring long-term commitment.
• An exercise price of $1.30, if it represents the fair market value on the grant date, is typical for incentive stock options.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with long-term company performance and value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth and success within the company.

Next Steps

• Minnie Kuo will continue to provide continuous service to the Issuer to ensure the vesting of the options.
• The company's operational and financial performance will determine the ultimate value realized from these options.

Key Dates

Recommendation

The grant of stock options to the Chief Operating Officer is a standard executive compensation practice designed to align management's interests with long-term shareholder value. While positive for executive retention and motivation, it does not present new fundamental information that would warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and monitor the company's operational and financial performance.

Keywords

PLIANT THERAPEUTICS, PLRX, Minnie Kuo, Stock Options, SEC Form 4, Executive Compensation, Derivative Securities, Insider Transaction